Fenner H
F. Hoffmann-La Roche & Co. Ltd., Basel, Switzerland.
Eur J Rheumatol Inflamm. 1987;9(2):3-7.
The chronicity of the inflammatory process requires persistent tissue concentrations of non-steroidal anti-inflammatory drugs (NSAIDs), best achieved by using a drug with a long half-life as a once-daily regimen. The oxicams proved to be one of the most promising classes of NSAIDs. They have a similar molecular structure, though substitution of the benzothiazine ring by a thienothiazine system gives tenoxicam a more hydrophilic character. Tenoxicam is thus characterised by lower penetration into tissues requiring more lipophilic properties, e.g. the CNS and skin and, consequently, a lower incidence of adverse reactions at these target organs. Poor diffusion into hepatic cells--as a result of a small free fraction, tight binding to proteins and hydrophilic character--explains its low hepatic extraction ratio and--as a consequence--a long half-life. Compared to indomethacin and diclofenac, the oxicams have a moderate inhibitory activity on the synthesis and release of prostaglandins; tenoxicam is half as active as piroxicam, reflecting the correspondent difference in their steady-state plasma concentrations.
炎症过程的慢性化需要非甾体抗炎药(NSAIDs)在组织中持续保持一定浓度,使用半衰期长的药物并采用每日一次的给药方案可最佳地实现这一点。昔康类药物被证明是最有前景的NSAIDs类别之一。它们具有相似的分子结构,不过用噻吩并噻嗪系统取代苯并噻嗪环使替诺昔康具有更亲水性的特性。因此,替诺昔康的特点是对需要更多亲脂性的组织(如中枢神经系统和皮肤)的渗透较低,因此在这些靶器官的不良反应发生率也较低。由于游离分数小、与蛋白质紧密结合和亲水性,替诺昔康向肝细胞的扩散较差,这解释了其肝提取率低以及因此半衰期长的原因。与吲哚美辛和双氯芬酸相比,昔康类药物对前列腺素的合成和释放具有中等抑制活性;替诺昔康的活性是吡罗昔康的一半,这反映了它们稳态血浆浓度的相应差异。